cd56 cd4 (Miltenyi Biotec)
Structured Review

Cd56 Cd4, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 30 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd56 cd4/product/Miltenyi Biotec
Average 99 stars, based on 30 article reviews
Images
1) Product Images from "NK cell immunotherapy administered at the time of HIV recrudescence is associated with viral control"
Article Title: NK cell immunotherapy administered at the time of HIV recrudescence is associated with viral control
Journal: bioRxiv
doi: 10.1101/2025.11.19.688897
Figure Legend Snippet: A) Schematic figure showing the overview of NK cell production and the overview of the mouse study timeline. Red circles on the timeline indicate blood collection, black dots indicate scheduled necropsies. Schematic of transgene design: MND promoter, CAR (CD4-MBL-CD8TM-4-1BB-CD3z), CXCR5, IL-15, the BgH PolyA tail, with separation mediated by P2A and T2A sites, and inverted terminal repeats (ITRs). Schematic showing expression of all transgene components as well as base editor-mediated knock out of PD-1 on the NK cell surface. Figure made using Biorender.com. B) Expression of CAR (MBL) and CXCR5 molecules was confirmed in the cell product using flow cytometry. Cells were pre-gated sequentially on lymphocytes, singlets, live cells, CD56+, and CD3-. C) PD-1 knockout was detected at the RNA level by RT-PCR, CAR NK (blue) relative to control NK cells (black). D) IL-15 expression in CAR NK (blue) and control NK (black) cells via IL-15 ELISA of cell culture supernatant. E) CAR (blue) and control (black) cell proliferation over one week post-thaw. F) The specific lysis of HIV Envelope P815s by CAR (blue) or control (black) NK cells via DELFIA cytotoxicity assay. 5:1, 10:1, and 20:1 E:T ratios were tested. All assays were performed in duplicate or triplicate. Data are represented as mean + standard deviation (error bars).
Techniques Used: Expressing, Knock-Out, Flow Cytometry, Reverse Transcription Polymerase Chain Reaction, Control, Enzyme-linked Immunosorbent Assay, Cell Culture, Lysis, Cytotoxicity Assay, Standard Deviation
Figure Legend Snippet: NK (CD56+) cells in CAR (blue), control (black), or PBS (red) treated groups from A) Peripheral Blood, B) Lymph node (at necropsies), and C) Spleen (at necropsies). CAR+CXCR5+ NK cells over time in D) Peripheral Blood, E) Lymph node (at necropsies), and F) Spleen (at necropsies). Flow was pre-gated on Lymphocytes, Singlets, Live Cells, human CD45+, mouse CD45-, CD3+, and then through CD56+ MBL+ CXCR5+ (see Fig. S4 for gating strategy). Median viral loads (green), NK cell levels (orange), post-treatment in G) controllers or H) non-controllers. I) Median human hematopoietic cell counts (CD45+)/ ul blood of controllers (gray) or non-controllers (pink).
Techniques Used: Control
Figure Legend Snippet: CD4:CD8 ratios over time in A) CAR NK-treated animals (blue), B) control NK-treated animals (black), and C) PBS-treated animals (red). CD4:CD8 ratios in CAR (blue), control NK (black), and PBS (red) treated groups at D) -6 DPT, E) 6 DPT, F) 14 DPT, G) 28 DPT, H) 42 DPT, and I) 56 DPT. Lines represent median values. CD4:CD8 ratios were determined by flow cytometry and pre-gated on Lymphocytes, Singlets, Live Cells, Human CD45+, Mouse CD45-, CD3+ (see gating strategy in Fig. S4 ).
Techniques Used: Control, Flow Cytometry
